HDAC6 and cerebral infarction: The association of HDAC6 inhibition with smaller cerebral infarction sizes was upheld in sensitivity analyses incorporating data from studies utilising (i) commercially available HDAC6 inhibitors and (ii) the most widely employed HDAC6 inhibitor (Tubastatin A, 25 mg/kg, Supplements 5 and 6).